SEC Form 4 · accession 0000899243-19-003310
T2 Biosystems, Inc. · TTOO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Terrence Gibbs
Officer — General Counsel
Period of report
Feb 9, 2019
Accepted (ET)
Feb 12, 2019 · 4:51 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001492674
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 9, 2019 | M | 5,834 | — | A | 60,262 | D | |
| Common StockF3 | Feb 11, 2019 | S | 3,005 | $3.36 | D | 57,237 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F4 | — | Feb 9, 2019 | M | 5,834 | A | — | — | Common Stock | 5,834 | 5,833 | D |
Explanation of responses
- F1Each restricted stock units ("RSU's") represents a contingent right to receive one share of the Issuer's common stock.
- F2The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2018.
- F3The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $3.31 to $3.40. The reporting person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F4On February 9, 2017 the reporting person was granted 17,500 RSU's that vested in three equal annual installments beginning on February 9, 2018.